title: Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients.
abstract: More than 4 million people are currently infected with Hepatitis C an RNA virus that may ultimately result in complete hepatic failure and is often a silent infection until late in the course of disease. Hepatitis C patients have increased rates of major depression (as well as substance abuse) and treatment of hepatitis with interferon, the current standard treatment, provokes episodes of depression in as many as a third of patients treated. Immune-dysfunction mediated mechanisms for the depression in these patients have been proposed and have increasing experimental support. The resulting depression has interfered with treatment for many patients, but several standard treatments for depression have been shown to be effective in patients with interferon-associated depression, suggesting that this should not be a barrier to effective treatment. In this paper, we review the evidence for associations between depression and Hepatitis C and interferon treatment, as well as the evidence supporting an immune mechanism for the association, and finally the data showing effective treatment and recommendations for prophylactic use of anti-depressants.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. aangelino@jhmi.edu
authors.forename: Andrew F
authors.initials: AF
authors.lastname: Angelino
authors.forename: Glenn J
authors.initials: GJ
authors.lastname: Treisman
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use; D001921:Brain / Q000503:physiopathology; D016207:Cytokines / Q000097:blood; D003865:Major Depressive Disorder / Q000139:chemically induced / Q000276:immunology* / Q000517:prevention & control; D006526:Hepatitis C / Q000188:drug therapy / Q000276:immunology / Q000523:psychology*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D007372:Interferons / Q000009:adverse effects* / Q000627:therapeutic use; D011598:Psychoneuroimmunology; D012306:Risk
chemical_list: D000928:Antidepressive Agents; D016207:Cytokines; D007372:Interferons